Mindful Innovation

Mastering Challenges.
Compassion for Patients.
Transforming Medicine.

At Marinus, our passionate team of experts are constantly innovating
with the aim to drastically improve lives affected by seizure disorders.

Ryan, living with CDKL5 deficiency disorder

Purple Ring

Commitment

Dedicated to driving forward innovation for seizure disorders

Learn more

Blue Ring

Innovation

Maximizing the reach of our therapeutics to make a difference in patients’ lives  

Learn more

Green Ring

Community

Engaging with leading epilepsy and seizure disorder patient advocacy groups 

Learn more

Expanded Access Program

Marinus launched the Expanded Access Program (EAP) for CDKL5 in January 2020.
This program allows qualified patients to receive the investigational drug ganaxolone for CDD.

We are committed to developing treatments for patients with severe, rare forms of epilepsy, implementing a clinical trial and commercial strategy that is guided by our strong scientific rationale, and unlocking new possibilities across a range of seizure disorders.

— Scott Braunstein, M.D., CEO, Marinus

  • Pipeline

    Discover the science behind our work

    Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.

    View our pipeline

  • Focus Areas

    Focused on seizure disorders

    We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, and CDKL5 deficiency disorder.

    Learn more about our focus areas

  • Trials

    Our goal is developing safe and effective treatments

    We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.

    Learn more about our active trials on ClinicalTrials.gov

Providing a range of clinical trials to develop innovative treatments for patients

Disability,a,disabled,child,in,a,wheelchair,being,looked,after

Status Epilepticus

Striving to maintain seizure control

Developing therapies with the potential to provide rapid cessation of status epilepticus and prevent escalation of treatment

Learn more

Rare Orphan Epilepsies

Aspiring to give children significantly less seizures and better quality of life

Developing treatment options with the potential to safely decrease seizure frequency in children with refractory epilepsy

Learn more

Advocacy & Related Activities

Fostering a community for those impacted by seizure disorders

Collaborating with key groups to support patients and their families, working to lessen the impact of seizure disorders

Learn more

Svg Graphic Neurology 1

Follow Us on Twitter

We’re honored to support @CDKL5USA’s 2nd annual Move #CDKL5 Forward initiative. Join Marinus employees and the global CDD community in getting out and moving this month to help raise awareness of CDKL5 deficiency disorder. http://CDKL5.com/move

This weekend our colleagues will be attending the @LGS_Foundation Family & Professional Conference, an event that brings together 350+ LGS family members and epilepsy professionals to better understand the causes, treatments and how to live with LGS.  https://bit.ly/3GmyvdO

Today, our CEO Scott Braunstein, M.D., and CFO Steve Pfanstiel will be speaking at the Jeffries Global Healthcare Conference in NYC. Join the webcast here: https://wsw.com/webcast/jeff240/mrns/1869600

Tsc Walk 2021 Compressed 1

Want to make an impact?

We are always looking for dedicated and passionate professionals who want to make a positive difference in the lives of those affected by seizure disorders

Join us